New hope for lung cancer patients when standard drugs fail
NCT ID NCT07206498
Summary
This study is testing whether adding a new experimental drug called WSD0922-FU to an existing lung cancer medication (osimertinib) is safe and can help control advanced non-small cell lung cancer. It is for patients whose cancer has spread or has developed specific genetic changes that make it resistant to current treatments. The main goals are to check for side effects and see if the combination can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, 200123, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.